Merck&Co

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 3 hours ago

Unsupported price hikes added $815 mln to US drug spending in 2023

UPDATE 1-Unsupported price hikes added $815 mln to US drug spending in 2023 Adds J&J's comment in paragraph 4 and 5, Gilead's comment in paragraph 8 By Sriparna Roy Dec 12 (Reuters) - Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday.

Reuters - 8 hours ago

Unsupported price hikes added $815 mln to US drug spending in 2023

Unsupported price hikes added $815 mln to US drug spending in 2023 By Sriparna Roy Dec 12 (Reuters) - Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday. The Institute for Clinical and Economic Review (ICER) said that half of the drugs assessed had price increases based on new evidence of additional benefi

Reuters - 9 hours ago

Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial

UPDATE 4-Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial Updates shares in paragraph 1, adds analyst comment in paragraph 8 By Sneha S K Dec 12 (Reuters) - Keros Therapeutics KROS.O said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a safety issue, sending its shares plunging 77%.

Reuters - 1 day ago

Candel's cancer therapy meets late-stage trial goal, shares soar

UPDATE 3-Candel's cancer therapy meets late-stage trial goal, shares soar Adds details from conference call in paragraphs 2,3,10, background throughout By Mariam Sunny and Kamal Choudhury Dec 11 (Reuters) - Candel Therapeutics' CADL.O experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company's shares more than double in value in early trading.

Reuters - 3 days ago

U.S. Jll, Mongodb, Rigel Pharmaceuticals

U.S. RESEARCH ROUNDUP-Jll, Mongodb, Rigel Pharmaceuticals Dec 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Jll, Mongodb and Rigel Pharmaceuticals, on Tuesday. HIGHLIGHTS * Jll JLL.N : KBW raises target price to $325 from $292 * Mongodb Inc MDB.O : Barclays raises target price to $400 from $375 * Rigel Pharmaceuticals Inc RIGL.O : B.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.